A phase l, first-in-human study evaluating the safety, tolerability, and efficacy of autologous T-cells carrying a Siglec-6-specific chimeric antigen receptor (CAR) in adult patients with Refractory or Relapsed (RR) Acute Myeloid Leukemia (AML) or Chronic Lymphocytic Leukemia (CLL)
A phase l, first-in-human study evaluating the safety, tolerability, and efficacy of autologous T-cells carrying a Siglec-6-specific chimeric antigen receptor (CAR) in adult patients with Refractory or Relapsed (RR) Acute Myeloid Leukemia (AML) or Chronic Lymphocytic Leukemia (CLL)
